JP2006506425A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506425A5
JP2006506425A5 JP2004552562A JP2004552562A JP2006506425A5 JP 2006506425 A5 JP2006506425 A5 JP 2006506425A5 JP 2004552562 A JP2004552562 A JP 2004552562A JP 2004552562 A JP2004552562 A JP 2004552562A JP 2006506425 A5 JP2006506425 A5 JP 2006506425A5
Authority
JP
Japan
Prior art keywords
methyl
ethyl
formula
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004552562A
Other languages
English (en)
Other versions
JP2006506425A (ja
Filing date
Publication date
Priority claimed from DE10253220A external-priority patent/DE10253220A1/de
Application filed filed Critical
Publication of JP2006506425A publication Critical patent/JP2006506425A/ja
Publication of JP2006506425A5 publication Critical patent/JP2006506425A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. 一般式Ｉの化合物。
    Figure 2006506425
     (式中、nは1、2または3のいずれかを表し、
    R1は-C1-C4-アルキルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、-C1-C4-アルキル、-OH、-O-C1-C4-アルキル、-C1-C4-アルキレン-ハロゲン、-C1-C4-アルキレン-OH、-C1-C4-アルキレン-O-C1-C4-アルキル、-CF3、-CHF2、-NH2、-NH(C1-C4-アルキル)、-N(C1-C4-アルキル)2、ハロゲン、-COOH、-COO-C1-C4-アルキル、-NHCO-C1-C4-アルキル、-NHSO2-C1-C4-アルキル、-SO2NH2のいずれかを表す。）
  2. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、メトキシ、エトキシ、-CH2F、-CH2Cl、-CH2Br、-CH2CH2F、−CH2CH2Cl、-CH2CH2Br、-CH2OH、-CH2CH2OH、-CH2Oメチル、−CH2CH2Oメチル、−CH2Oエチル、-CH2CH2Oエチル、-CF3、-CHF2、-NH2、-NHメチル、-NHエチル、-N(メチル)2、-N(エチル)2、フッ素、塩素、臭素、-COOH、−COOメチル、-COOエチル、-NHCO-メチル、−NHCO-エチル、-NHSO2-メチル、-NHSO2-エチルのいずれかで表される、請求項1記載の式Ｉの化合物。
  3. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、メトキシ、エトキシ、-CH2F、-CH2CH2F、-CH2OH、-CH2CH2OH、-CH2Oメチル、−CH2CH2Oメチル、−CH2Oエチル、-CH2CH2Oエチル、-CF3、-CHF2のいずれかで表される、請求項1または2に記載の式Ｉの化合物。
  4. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、メトキシ、エトキシ、-CF3、-CHF2のいずれかで表される、請求項1〜3のいずれか1項に記載の式Ｉの化合物。
  5. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、エチル、-OH、-CF3のいずれかで表される、請求項1〜4のいずれか1項に記載の式Ｉの化合物。
  6. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2、R3及びR4は同一でも異なっていてもよく、水素、メチル、-OHのいずれかで表される、請求項1〜5のいずれか1項に記載の式Ｉの化合物。
  7. 式中、nが1または2を表し、
    R1がメチルもしくはエチルを表し、
    R2が水素を表し、
    R3及びR4は同一でも異なっていてもよく、水素、メチル、-OHのいずれかで表される、請求項1〜6のいずれか1項に記載の式Ｉの化合物。
  8. 単一光学異性体、単一鏡像異性体混合物またはラセミ体の形を取り、また、遊離塩基もしくは薬理学的に許容しうる酸との対応する酸付加塩の形を取る、請求項1〜7のいずれか1項に記載の式Ｉの化合物。
  9. 治療上有効量のベータミメティックの投与が治療効果を及ぼすような疾患の治療用医薬組成物を調製するための請求項1〜8のいずれか1項に記載の一般式Ｉの化合物の使用。
  10. 請求項1〜8のいずれか1項に記載の式Ｉの化合物を1つ又はそれ以上含むことを特徴とする医薬製剤。
JP2004552562A 2002-11-15 2003-11-11 新規ジヒドロキシ−メチルフェニル誘導体、その製造方法及び薬剤としてのその使用 Pending JP2006506425A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10253220A DE10253220A1 (de) 2002-11-15 2002-11-15 Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
PCT/EP2003/012566 WO2004046083A1 (de) 2002-11-15 2003-11-11 Neue dihydroxy-methyl-phenyl-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel

Publications (2)

Publication Number Publication Date
JP2006506425A JP2006506425A (ja) 2006-02-23
JP2006506425A5 true JP2006506425A5 (ja) 2007-01-11

Family

ID=32185693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004552562A Pending JP2006506425A (ja) 2002-11-15 2003-11-11 新規ジヒドロキシ−メチルフェニル誘導体、その製造方法及び薬剤としてのその使用

Country Status (7)

Country Link
US (1) US7135500B2 (ja)
EP (1) EP1562892A1 (ja)
JP (1) JP2006506425A (ja)
AU (1) AU2003282094A1 (ja)
CA (1) CA2506109A1 (ja)
DE (1) DE10253220A1 (ja)
WO (1) WO2004046083A1 (ja)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
KR101058696B1 (ko) * 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
DE102004003428A1 (de) * 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
US7220742B2 (en) * 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CA2618089A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
ES2530991T3 (es) * 2005-08-15 2015-03-09 Boehringer Ingelheim Int Procedimiento para la obtención de betamiméticos
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
ATE502943T1 (de) 2006-09-29 2011-04-15 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
KR20090075714A (ko) 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
EA201101492A1 (ru) * 2006-11-15 2012-09-28 Вирокем Фарма Инк. Аналоги тиофена для лечения или предупреждения флавивирусных инфекций
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
EA200901489A1 (ru) 2007-05-07 2010-04-30 Новартис Аг Органические соединения
AU2008334629B2 (en) 2007-12-10 2012-04-12 Novartis Ag Organic compounds
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
NZ594157A (en) 2008-12-30 2013-07-26 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (ja) 2009-08-20 2015-06-05 Novartis Ag
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755967B1 (en) 2011-09-16 2015-10-21 Novartis AG Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
ES2667424T3 (es) 2014-04-24 2018-05-10 Novartis Ag Derivados de pirazina como inhibidores de fosfatidil-inositol-3-quinasa
BR112016024533A8 (pt) 2014-04-24 2021-03-30 Novartis Ag derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
US20220306617A1 (en) 2019-08-28 2022-09-29 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1543372A1 (de) * 1966-10-18 1971-04-01 Boehringer Sohn Ingelheim Verfahren zur Herstellung von o-substituierten 3,4-Dioxyphenylalkanolaminen
US4042713A (en) * 1966-10-18 1977-08-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing a 1-(2-alkyl-3,4-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanol-(1) and method of use
US3969410A (en) * 1972-01-12 1976-07-13 Boehringer Ingelheim Gmbh 1-(2'-Alkyl-3',4'-dihydroxy-phenyl)-2-(phenylalkyl-amino)-alkanols-(1) and salts thereof
LU85856A1 (fr) * 1984-04-17 1986-06-11 Glaxo Group Ltd Composes de phenethanolamine
US5223614A (en) * 1987-12-19 1993-06-29 Boehringer Ingelheim Gmbh New quaternary ammonium compounds, their preparation and use
EA200201056A1 (ru) 2000-04-27 2003-04-24 Бёрингер Ингельхайм Фарма Кг Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств

Similar Documents

Publication Publication Date Title
JP2006506425A5 (ja)
JP2016534063A5 (ja)
JP2017528503A5 (ja)
JP2018518537A5 (ja)
JP2006526590A5 (ja)
JP2005516067A5 (ja)
JP2005525323A5 (ja)
JP2010503688A5 (ja)
JP2008512408A5 (ja)
JP2009541209A5 (ja)
JP2003531118A5 (ja)
JP2005525322A5 (ja)
JP2014515351A5 (ja)
JP2006182786A5 (ja)
JP2012525393A5 (ja)
JP2005515964A5 (ja)
JP2006526031A5 (ja)
JP2014500861A5 (ja)
JP2008513510A5 (ja)
JP2007525533A5 (ja)
JP2005524605A5 (ja)
JP2012532883A5 (ja)
JP2010526827A5 (ja)
JP2019529541A5 (ja)
RU2007138582A (ru) Пероральные дозированные формы производных гемцитабина